$ALMR earnings report

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance. AlphAI read Alamar Biosciences's Third Quarter 2026 filing as mixed. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readALMR · Third Quarter 2026 · ended September 30, 2026

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

→Mixed quarter

Third-quarter revenue grew 68%, gross margin expanded, and the company raised full-year revenue guidance, but operating expenses grew 81% and net loss widened to $13.3 million.

Revenue
$33.5M
68% y/y
Instruments, three months ended September 30, 2026
$8.5M
50% y/y
Gross margin · GAAP
61.5%
EPS · GAAP
$ (0.19 )
Full year 2026 outlook
$121 to $123 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30, 2026GAAP$33.5M–68%
Product revenue, three months ended September 30, 2026GAAP$26.3M––
Service and other revenue, three months ended September 30, 2026GAAP$7.25M–69%
Total cost of revenue, three months ended September 30, 2026GAAP$12.90M––
Cost of product revenue, three months ended September 30, 2026GAAP$10.88M––
Cost of service and other revenue, three months ended September 30, 2026GAAP$2.02M––
Gross profit, three months ended September 30, 2026GAAP$20.64M––
Gross margin, three months ended September 30, 2026GAAP61.5%––
Research and development expense, three months ended September 30, 2026GAAP$16.17M––
Selling, general and administrative expense, three months ended September 30, 2026GAAP$19.62M––
Total operating expenses, three months ended September 30, 2026GAAP$35.8M–81%
Loss from operations, three months ended September 30, 2026GAAP$15.1 million operating loss––
Interest income, net, three months ended September 30, 2026GAAP$2.17M––
Interest expense, three months ended September 30, 2026GAAP−$153K––
Other expense, net, three months ended September 30, 2026GAAP−$125K––
Net loss before income tax, three months ended September 30, 2026GAAP−$13.25M––
Provision for income taxes, three months ended September 30, 2026GAAP$94K––
Net loss, three months ended September 30, 2026GAAP$13.3M––
Net loss per share, basic and diluted, three months ended September 30, 2026GAAP$ (0.19 )––
Weighted-average common shares outstanding, basic and diluted, three months ended September 30, 2026GAAP69,106,367––
Total stock-based compensation expense, three months ended September 30, 2026GAAP$3.92M––
Total revenue, nine months ended September 30, 2026GAAP$89.01M––
Product revenue, nine months ended September 30, 2026GAAP$70.91M––
Service and other revenue, nine months ended September 30, 2026GAAP$18.10M––
Total cost of revenue, nine months ended September 30, 2026GAAP$36.19M––
Gross profit, nine months ended September 30, 2026GAAP$52.82M––
Research and development expense, nine months ended September 30, 2026GAAP$43.00M––
Selling, general and administrative expense, nine months ended September 30, 2026GAAP$50.84M––
Total operating expenses, nine months ended September 30, 2026GAAP$93.84M––
Loss from operations, nine months ended September 30, 2026GAAP−$41.02M––
Loss on remeasurement of convertible notes, nine months ended September 30, 2026GAAP−$9.97M––
Net loss, nine months ended September 30, 2026GAAP−$47.87M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$ (1.02 )––
Weighted-average common shares outstanding, basic and diluted, nine months ended September 30, 2026GAAP46,884,564––
Total stock-based compensation expense, nine months ended September 30, 2026GAAP$8.66M––

Segments

SegmentRevenueq/qy/y
Instruments, three months ended September 30, 2026Driven primarily by continued growth in new instrument placements.$8.5M–50%
Consumables, three months ended September 30, 2026Driven primarily by strong demand for multiplex panels.$17.8M–79%
Services and other, three months ended September 30, 2026Driven primarily by strong demand for custom assay development services.$7.2M–69%
Instruments, nine months ended September 30, 2026No nine-month driver was provided.$23.64M––
Consumables, nine months ended September 30, 2026No nine-month driver was provided.$47.27M––
Services, nine months ended September 30, 2026No nine-month driver was provided.$18.10M––
Other revenue, nine months ended September 30, 2026No nine-month driver was provided.—––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full year 2026 outlook

  • Revenue$121 to $123 million
  • NoteRepresenting growth of 64% at the midpoint of the range compared to full year 2025.

What drove it

  • Biopharma customers accounted for the largest portion of revenue for the first time.
  • New instrument placements supported instrument revenue growth.
  • Strong demand for multiplex panels supported consumable revenue growth.
  • Strong demand for custom assay development services supported services and other revenue growth.
  • Gross-margin expansion was attributed to lower instrument costs, higher average selling prices for consumables, improved margins on services, and a favorable shift in product mix.
  • Operating-expense growth reflected planned investments in headcount, infrastructure and R&D supplies, as well as incremental public company costs.
  • UK Biobank selected Alamar to profile 80,000 samples for a study targeting neurodegenerative conditions.
  • Alamar launched a strategic scientific collaboration with GSK for a large-scale 60,000-sample study.

Concerns

  • Operating expenses increased 81% to $35.8 million, exceeding total revenue of $33.5 million.
  • Operating loss widened to $15.1 million from an operating loss of $7.9 million.
  • Net loss widened to $13.3 million from an $8.0 million net loss.
  • The nine-month period included a $ (9,971 ) (in thousands) loss on remeasurement of convertible notes.
  • The company identified risks including intense competition in the proteomics market, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, manufacturing complexity, and potential regulatory requirements.

What to watch

  • Execution against full-year 2026 revenue guidance of $121 to $123 million.
  • Whether biopharma customers remain the largest portion of revenue.
  • New instrument placements and associated consumable demand.
  • Realization of the cited gross-margin benefits from instrument costs, consumable pricing, services margins, and product mix.
  • Spending on headcount, infrastructure, R&D supplies and public company costs.
  • Transition following President Tod White’s retirement at the end of 2026 and his advisory role through June 2027.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 121,532 (in thousands) as of September 30, 2026, compared with $ 30,002 (in thousands) as of December 31, 2025.
  • Short-term investments were $ 105,053 (in thousands) as of September 30, 2026, compared with — as of December 31, 2025.
  • Restricted cash was $ 4,907 (in thousands) as of September 30, 2026 and $ 4,907 (in thousands) as of December 31, 2025.
  • Cash, cash equivalents, short-term investments and restricted cash were $231.5 million as of September 30, 2026.
  • Accounts receivable were $ 21,611 (in thousands), compared with $ 12,753 (in thousands) as of December 31, 2025.
  • Inventory was $ 54,133 (in thousands), compared with $ 38,482 (in thousands) as of December 31, 2025.
  • Total assets were $ 378,027 (in thousands), compared with $ 139,992 (in thousands) as of December 31, 2025.
  • Accounts payable were $ 16,549 (in thousands), compared with $ 5,872 (in thousands) as of December 31, 2025.
  • Total liabilities were $ 74,323 (in thousands), compared with $ 63,950 (in thousands) as of December 31, 2025.
  • Term debt was — as of September 30, 2026, compared with $ 9,810 (in thousands) as of December 31, 2025.
  • Total stockholders’ equity (deficit) was $ 303,704 (in thousands), compared with $ (158,954 ) (in thousands) as of December 31, 2025.

Analysis

Alamar reported $33.5 million of third-quarter revenue, up 68% from $19.9 million in the corresponding prior-year period. Growth was broad across the reported revenue sources: instrument revenue grew 50% to $8.5 million, consumable revenue grew 79% to $17.8 million, and services and other revenue grew 69% to $7.2 million. Management said biopharma customers accounted for the largest portion of revenue for the first time, while new instrument placements, multiplex-panel demand, and custom assay development services were the stated revenue drivers.

The revenue mix supported improved gross profitability. Gross margin increased to 61.5% from 59.7%, which the company attributed to lower instrument costs, higher average selling prices for consumables, improved services margins, and a favorable product-mix shift. Gross profit was $ 20,644 (in thousands), compared with $ 11,897 (in thousands) in the prior-year quarter. The nine-month results showed $ 89,007 (in thousands) in total revenue and $ 52,819 (in thousands) in gross profit.

Investment spending remained substantial. Total operating expenses rose 81% to $35.8 million, driven by planned headcount, infrastructure and R&D-supply investments and incremental public company costs. Research and development expense was $ 16,167 (in thousands), selling, general and administrative expense was $ 19,616 (in thousands), and total stock-based compensation expense was $ 3,916 (in thousands). As a result, operating loss widened to $15.1 million from $7.9 million and net loss widened to $13.3 million from $8.0 million.

Liquidity was supported by $231.5 million of cash, cash equivalents, short-term investments and restricted cash as of September 30, 2026. The balance sheet reported no term debt at September 30, 2026, versus $ 9,810 (in thousands) at December 31, 2025. The company raised full-year 2026 revenue guidance to $121 to $123 million from previous expectations of $116 to $120 million. Operationally, investors will focus on execution against that range, continued instrument placements and consumable demand, the expansion of biopharma revenue, and the company’s ability to sustain gross-margin improvement while managing operating-expense growth.

The company also announced that President Tod White will retire at the end of 2026 and will serve as an advisor through June 2027. Commercial developments included selection by UK Biobank to profile 80,000 samples and a strategic scientific collaboration with GSK for a 60,000-sample study. These developments accompany the company’s stated demand momentum but do not alter the reported operating loss and continued investment profile.

Management, verbatim

Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time.

Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences

Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.

Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences

It has been a privilege to work alongside this exceptional team. Their talent, dedication, and belief in what precision proteomics can do to improve human health have driven everything we have accomplished. Alamar is well positioned to lead the next era of proteomics, and I have never been more confident in the company’s future.

Tod White, president

Not in the filing

stated, not guessed
  • Non-GAAP revenue, gross margin, operating income or loss, net income or loss, and EPS were not reported.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Capital expenditures were not reported.
  • Share repurchases and dividends were not reported.
  • A tax-rate guidance figure was not reported.
  • Gross-margin guidance and operating-expense guidance were not reported.
  • Prior-quarter comparisons were not reported for the financial metrics.
  • The previous outlook covered the full year 2026 only, and this quarterly release cannot be compared with full-year guidance.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second quarter of 2026

AlphAI · Earnings readALMR · Second quarter of 2026 · ended June 30, 2026

Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance

✓Solid quarter

Total revenue increased 82%, consumable revenue grew 147%, and gross margin expanded to 60%, while operating expenses increased 89% and net loss widened to $13.2 million.

Revenue
$29.4M
82% increase y/y
Instruments
$7.8M
35% y/y
Gross margin · GAAP
60%
EPS · GAAP
$(0.22)
Full year 2026 outlook
$116 million to $120 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$29.4M–82% increase
Product revenueGAAP$23.27M––
Service and other revenueGAAP$6.16M––
Total cost of revenueGAAP$11.71M––
Gross profitGAAP$17.72M––
Gross marginGAAP60%––
Research and development expenseGAAP$13.82M––
Selling, general and administrative expenseGAAP$17.43M––
Total operating expensesGAAP$31.2M–89% increase
Operating lossGAAP$13.5M––
Interest income, netGAAP$1.88M––
Interest expenseGAAP$(224)––
Loss on remeasurement of convertible notesGAAP−$1.38M––
Net lossGAAP$13.2M––
Net loss per share, basic and dilutedGAAP$(0.22)––
Weighted-average common shares outstanding, basic and dilutedGAAP58,665,055––
Total stock-based compensation expenseGAAP$3.3M––
Cash, cash equivalents, short-term investments and restricted cashother$256.3M––

Segments

SegmentRevenueq/qy/y
InstrumentsDriven primarily by continued growth in new instrument placements.$7.8M–35%
ConsumablesDriven primarily by strong demand for multiplex panels.$15.5M–147%
Services and other revenueDriver not specified.$6.2M–49%

Full year 2026 outlook

  • Revenue$116 million to $120 million
  • NoteGrowth of 59% at the midpoint of the range compared to full year 2025.

What drove it

  • Consumable revenue grew 147%, driven primarily by strong demand for multiplex panels.
  • Instrument revenue grew 35%, driven primarily by continued growth in new instrument placements.
  • Gross-margin expansion was primarily driven by manufacturing efficiencies for consumables and a favorable shift in mix toward high-margin consumables.
  • The company launched the first commercial multiplexed blood-based immunoassay for eMTBR-tau and launched the NULISAseq™ Immune 340 Panel.

Concerns

  • Operating expenses increased 89% to $31.2 million, primarily related to planned investments in headcount, infrastructure and R&D capabilities as well as incremental public company costs.
  • Net loss increased to $13.2 million from a $7.0 million net loss.
  • The quarter included a $1,377 loss on remeasurement of convertible notes.
  • The filing identifies risks including intense competition in the proteomics market, dependence on researchers who rely heavily on government funding, reductions in research and academic-institution spending, and manufacturing complexity.

What to watch

  • Demand for multiplex panels and the resulting consumable-revenue trajectory.
  • New instrument placements and their contribution to instrument revenue.
  • Whether manufacturing efficiencies and the mix toward high-margin consumables support gross margin.
  • Adoption of eMTBR-tau and the NULISAseq™ Immune 340 Panel.
  • Progress toward full-year 2026 revenue guidance of $116 million to $120 million.
  • The pace of spending on headcount, infrastructure and R&D capabilities.

Balance sheet and cash flow

  • Cash and cash equivalents were $132,969 as of June 30, 2026.
  • Short-term investments were $117,083 as of June 30, 2026.
  • Restricted cash was $6,254 as of June 30, 2026.
  • Term debt was $9,947 as of June 30, 2026.
  • No operating cash flow, free cash flow, repurchases, or dividends were reported.

Analysis

Alamar reported $29.4 million of second-quarter revenue, up 82% from $16.2 million in the corresponding prior-year period. Growth was led by consumables, which rose 147% to $15.5 million on strong demand for multiplex panels. Instrument revenue increased 35% to $7.8 million, driven primarily by new instrument placements, while services and other revenue increased 49% to $6.2 million.

The revenue mix supported profitability at the gross-profit level. Gross margin increased to 60% from 53%, with the company attributing the improvement to consumables manufacturing efficiencies and a favorable shift toward high-margin consumables. Gross profit was $17,718, compared with $8,581 in the prior-year quarter, based on the condensed consolidated statements of operations.

Operating investment rose faster than revenue. Operating expenses increased 89% to $31.2 million, reflecting planned investments in headcount, infrastructure and R&D capabilities as well as incremental public company costs. Operating loss was $13.5 million versus an operating loss of $7.9 million, and net loss was $13.2 million compared with a $7.0 million net loss. The quarter included $3.3 million of stock-based compensation and a $1,377 loss on remeasurement of convertible notes.

Liquidity was $256.3 million in cash, cash equivalents, short-term investments and restricted cash as of June 30, 2026. The company provided full-year 2026 revenue guidance of $116 million to $120 million, representing growth of 59% at the midpoint compared with full-year 2025. The key operating indicators are sustained consumables demand, continued instrument placements, commercialization of eMTBR-tau and the Immune 340 Panel, and the relationship between spending growth and further gross-margin expansion.

Management, verbatim

We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year.

Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences

With the recent launches of eMTBR-tau and the Immune 340 Panel strengthening our content menu and extending into new disease areas, we believe we are well-positioned to sustain momentum into the coming quarters.

Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences

Not in the filing

stated, not guessed
  • Previous-quarter revenue, segment revenue, gross margin, operating expenses, operating loss, net loss, EPS, and cash-flow comparisons were not reported.
  • Non-GAAP revenue, gross margin, operating income or loss, net income or loss, and EPS were not reported.
  • Operating cash flow and free cash flow were not reported.
  • Share repurchases and dividends were not reported.
  • Guidance for gross margin, operating expenses, tax rate, EPS, operating cash flow, or free cash flow was not reported.
  • Prior guidance was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ALMR earnings dates

When is Alamar Biosciences's next earnings date?
AlphAI has no date for ALMR yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.